{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:33:50Z","timestamp":1789994030094,"version":"4.0.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0180762","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T13:38:38Z","timestamp":1500471518000},"page":"e0180762","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":168,"title":["Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial"],"prefix":"10.1371","volume":"12","author":[{"given":"Eric J.","family":"Tarcha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-1882","authenticated-orcid":true,"given":"Chelsea M.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto J.","family":"Mu\u00f1oz-El\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn P.","family":"Iadonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0605136103","article-title":"Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases","volume":"103","author":"C Beeton","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0041-0101(95)00013-C","article-title":"Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus","volume":"33","author":"O Casta\u00f1eda","year":"1995","journal-title":"Toxicon"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"269rv1","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"RA Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12026-013-8448-1","article-title":"Autoimmune effector memory T cells: the bad and the good","volume":"57","author":"P Devarajan","year":"2013","journal-title":"Immunol Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1172\/JCI16921","article-title":"The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS","volume":"111","author":"H Wulff","year":"2003","journal-title":"J Clin Invest"},{"key":"ref6","first-page":"4563","article-title":"Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes","volume":"179","author":"L Hu","year":"2007","journal-title":"J Immunol Baltim Md 1950"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cbpa.2017.02.015","article-title":"Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease","volume":"38","author":"KG Chandy","year":"2017","journal-title":"Curr Opin Chem BIol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"14644","DOI":"10.1038\/ncomms14644","article-title":"Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions","volume":"8","author":"EY Chiang","year":"2017","journal-title":"Nat Commun"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.173.2.776","article-title":"K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity","volume":"173","author":"H Wulff","year":"2004","journal-title":"J Immunol"},{"key":"ref10","first-page":"214","article-title":"Voltage-gated ion channels as drug targets","author":"KG Chandy","year":"2006"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.immuni.2008.07.015","article-title":"Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block","volume":"29","author":"MP Matheu","year":"2008","journal-title":"Immunity"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"TD Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref13","first-page":"CD005028","article-title":"Topical treatments for chronic plaque psoriasis","volume":"3","author":"AR Mason","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-013-0015-y","article-title":"Systematic review of UV-based therapy for psoriasis","volume":"14","author":"F Almutawa","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2014.1111","article-title":"Combined use of systemic agents for psoriasis: a systematic review","volume":"150","author":"C Busard","year":"2014","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"A Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40257-013-0053-5","article-title":"Safety and tolerability of tumor necrosis factor-\u03b1 inhibitors in psoriasis: a narrative review","volume":"15","author":"AL Semble","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","article-title":"A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis","volume":"6","author":"M Campa","year":"2016","journal-title":"Dermatol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with sepcific targeting of interleukin-23","volume":"521","author":"T Kopp","year":"2015","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011","volume":"149","author":"AW Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref21","first-page":"1","article-title":"Psoriasis: from pathogenesis to novel therapeutic approaches","volume":"120","author":"G Monteleone","year":"2011","journal-title":"Clin Sci Lond Engl 1979"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"CN Ellis","year":"2001","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/exd.12154","article-title":"Circulating CLA+ T lymphocytes as peripheral cell biomarkers in T-cell-mediated skin diseases","volume":"22","author":"M Ferran","year":"2013","journal-title":"Exp Dermatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/187152811797200641","article-title":"Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases","volume":"10","author":"C Beeton","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/toxins7051749","article-title":"Toxins targeting the Kv1.3 channel: potential immunomodulators for autoimmune diseases","volume":"7","author":"Y Zhao","year":"2015","journal-title":"Toxins"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"O Arican","year":"2005","journal-title":"Mediators Inflamm"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"MA Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.4049\/jimmunol.151.8.4399","article-title":"Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro","volume":"151","author":"BS Schulz","year":"1993","journal-title":"J Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/jhg.2015.100","article-title":"Associations of human leukocyte antigens with autoimmune diseases: challenges in identifying the mechanism","volume":"60","author":"H Miyadera","year":"2015","journal-title":"J Hum Genet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: the dark side of a great activator","volume":"21","author":"AL Peters","year":"2009","journal-title":"Semin Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nn.2143","article-title":"Pungent agents from Szechuan peppers excite sensory neurons by inhibiting two-pore potassium channels","volume":"11","author":"DM Bautista","year":"2008","journal-title":"Nat Neurosci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1523\/JNEUROSCI.4666-09.2010","article-title":"Physiological basis of tingling paresthesia evoked by hydroxy-alpha-sanshool","volume":"30","author":"RC Lennertz","year":"2010","journal-title":"J Neurosci"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00424-014-1664-2","article-title":"The CNS under pathophysiologic attack\u2014examining the role of K2P channels","volume":"467","author":"P Ehling","year":"2015","journal-title":"Pflugers Arch"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1152\/jn.91053.2008","article-title":"Participation of Kv1 channels in control of membrane excitability and burst generation in mesencephalic V neurons","volume":"101","author":"C-F Hsiao","year":"2009","journal-title":"J Neurophysiol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1756285613512712","article-title":"4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review","volume":"7","author":"HB Jensen","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14740338.2012.697896","article-title":"Clinical overview of the seizure risk of dalfampridine","volume":"11","author":"SR Haut","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0028-3908(89)90056-7","article-title":"Distribution of the 4-aminopyridine derivative 3-methoxy-4-aminopyridine in mice","volume":"28","author":"SG Berger","year":"1989","journal-title":"Neuropharmacology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0196-9781(01)00537-X","article-title":"Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability","volume":"22","author":"KA Witt","year":"2001","journal-title":"Peptides"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.112.191890","article-title":"Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease","volume":"342","author":"EJ Tarcha","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/jid.2009.391","article-title":"How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review","volume":"130","author":"PI Spuls","year":"2010","journal-title":"J Invest Dermatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.4049\/jimmunol.1103095","article-title":"Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis","volume":"188","author":"AR Gocke","year":"2012","journal-title":"J Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/17425251003641967","article-title":"Alefacept: where it stands today","volume":"6","author":"J Chaarani","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref43","first-page":"1","article-title":"Alefacept treatment for chronic plaque psoriasis","volume":"15","author":"LK Dunn","year":"2010","journal-title":"Skin Ther Lett"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"JR Abrams","year":"1999","journal-title":"J Clin Invest"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.toxicon.2011.07.016","article-title":"Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases","volume":"59","author":"V Chi","year":"2012","journal-title":"Toxicon"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0180762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T12:04:26Z","timestamp":1692878666000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0180762"}},"subtitle":[],"editor":[{"given":"Heinz","family":"Wiendl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0180762","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}